how long for glp-1 side effects Your guide to GLP-1 Side Effects Statistics 2026

Stephens, T., et al

Patients who switched from tirzepatide to orforglipron maintained a mean 74.7% of their body weight reduction from the SURMOUNT-5 trial compared with those in the placebo group, which maintained a mean 49.2% of their weight loss

Cell Rep

Price and access will shape real-world impact

Understanding this regulatory status helps contextualize vendor sourcing considerations

Food and Drug Administration (FDA) This could include drugs such as semaglutide (the active ingredient in Ozempic and Wegovy), According to the FDAs announcement, the organization is asking for submitted comments for or against this decision by the end of June 2026 before making their final determination